- Home
- REKR vs CGTX Comparison
REKR vs CGTX Comparison
Compare REKR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REKR | CGTX |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | REKR | CGTX |
|---|---|---|
| Price | $1.55 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | ★ 2.8M | 897.3K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,028,000.00 | N/A |
| Revenue This Year | $11.82 | N/A |
| Revenue Next Year | $22.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.89 | N/A |
| 52 Week Low | $0.62 | $0.22 |
| 52 Week High | $3.42 | $3.83 |
Technical Indicators
Market Signals| Indicator | REKR | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 44.38 |
| Support Level | $1.37 | $1.33 |
| Resistance Level | $1.65 | $1.62 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 54.41 | 25.00 |
Price Performance
Historical ComparisonAbout REKR Rekor Systems Inc.
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which a majority of its revenue comes from the United States.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.